Merck KGaA, Darmstadt, Germany, appoints Jasper Bos as Managing Director of M Ventures
- Jasper Bos is currently heading M Ventures’ healthcare fund
- Succeeds Roel Bulthuis, who will leave the company at the end of 2018
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the appointment of Jasper Bos as the new Managing Director of its strategic corporate venture capital arm M Ventures. He will follow Roel Bulthuis as the Senior Vice President and Managing Director of M Ventures. Bulthuis will be leaving the fund at the end of the year.
“We thank Roel for his immense contribution in building M Ventures as a leading corporate venture fund and wish him all the best for his future endeavors,” said Isabel De Paoli, Chief Strategy Officer at Merck KGaA, Darmstadt, Germany, also responsible for M Ventures. “M Ventures is an important strategic lever in our ambitions to push the edge of science and technology. We are glad to be able to fill the role with an internal talent and experienced investor. Jasper Bos has been with M Ventures since 2009 and is crucial to the success of the healthcare fund, which he will continue to lead.”
“What excites me most about my work for M Ventures is the active role we play in our portfolio companies, which is all about supporting our entrepreneurs in realizing their ambitions and dreams,” Bos said.
Jasper Bos joined Merck KGaA, Darmstadt, Germany’s previous biopharma fund of M Ventures in 2009 and transitioned to Vice President leading the healthcare team for the current fund in 2016. At M Ventures, Bos supported (amongst others) the early successful investments and exits in ObsEva (NASDAQ-IPO), EpiTherapeutics (sale to Gilead), and was an initiator of Prexton Therapeutics, which was acquired early 2018 by Lundbeck for close to US$ 1.1 billion. He holds a PhD in Pharmacy from the University of Groningen, the Netherlands, and has previously worked in private equity and at the Netherlands Vaccine Institute.
In alignment with the strategic interests of Merck KGaA, Darmstadt, Germany’s business sectors, though formally separated by a “Chinese Wall”, M Ventures has the mandate to invest into the four sector-focused areas Healthcare, Life Science, Performance Materials and New Businesses. The total volume of M Ventures is € 300 million in an evergreen structure. Recent investments of M Ventures include, among numerous others, Artios, Galecto, Ribometrix, CLEARink Displays, DNAScript, Mosa Meat and Akili Interactive.
More information about M Ventures and its portfolio companies can be found at www.m-ventures.com.
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
Merck KGaA, Darmstadt, Germany, the vibrant science and technology company, operates across healthcare, life science and performance materials. Around 53,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enable the intelligence of devices – the company is everywhere. In 2017, Merck KGaA, Darmstadt, Germany, generated sales of € 15.3 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the company operates as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, has launched the VirusExpress® 293 Adeno-Associated Virus (AAV) Production Platform...